Cellect Biotechnology was founded in 2011 with a mission to become a global leader in the next generation of cellular therapies by developing innovative solutions for immune system regeneration.
Achieving higher selectivity, greater specificity and decreased toxicity, Cellect envisions its products becoming an integral and essential part of Bone Marrow Transplantation (BMT), as well as integrated into many aspects of regenerative medicine.
HEMATOPOIETIC STEM CELLS
STEM CELL TRANSPLANTATION
GRAFT VERSUS HOST DISEASE
Interested in our innovative technology?
Cellect Receives Israeli Ministry of Health Approval to Initiate Phase I/II Clinical Trial in Leukemia Patients
Company’s innovative cell selection product may dramatically reduce bone marrow transplantation risks Patient enrollment expected to begin in the next few weeks Tel Aviv, Israel – September 13, 2016 – Cellect Biotechnology Ltd. (Nasdaq: APOP, TASE: APOP), a developer of innovative technology which enables the functional selection of stem cells, today announced that the Company […]
Cellect Biotechnology Ltd Provides Corporate Update and Reports Second Quarter 2016 Financial Results
Raised Gross Proceeds of $8.4 Million through Pricing of July U.S. Initial Public Offering Tel Aviv, Israel – September 1, 2016 – Cellect Biotechnology Ltd. (NASDAQ: “APOP”, TASE: “APOP”), a developer of innovative technology which enables the functional selection of stem cells, today provided a corporate update and announced financial results for the second […]